×
About 1,998 results

ALLMedicine™ Systemic Mastocytosis Center

Research & Reviews  483 results

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

Aug 4th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

Health-related quality of life and health literacy in patients with systemic mastocytos...
https://doi.org/10.1186/s13023-022-02439-x
Orphanet Journal of Rare Diseases; Schmidt TJ, Sellin J et. al.

Jul 30th, 2022 - Systemic mastocytosis is a rare genetic disease characterized by aberrant proliferation and/or activation of mast cells, resulting in multi-organ, allergy-like symptoms. Mast cell activation syndrome (MCAS) is a clinically similar, but more preval...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

Jul 28th, 2022 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

Avapritinib for Advanced Systemic Mastocytosis.
https://doi.org/10.1182/blood.2021014612
Blood Gotlib J, Reiter A et. al.

Jul 26th, 2022 - Avapritinib, a selective inhibitor of KIT D816V, was approved by the Food and Drug Administration in 2021 for treatment of advanced systemic mastocytosis (AdvSM), and by the European Medicines Agency in 2022 for AdvSM patients after prior systemic...

A case of annular erythema of infancy accompanied by elevated tryptase.
https://doi.org/10.1111/pde.15037
Pediatric Dermatology; Kingsley JT, Lee EB et. al.

Jul 22nd, 2022 - Annular erythema of infancy (AEI) is characterized by self-limited eruptions of erythematous, annular to polycyclic patches and plaques, the etiology of which is thought to involve a hypersensitivity reaction to an unknown antigen. We present a ca...

see more →

Guidelines  1 results

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.

Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...

see more →

Drugs  207 results see all →

Clinicaltrials.gov  43 results

Study of Mast Cell Precursors
https://clinicaltrials.gov/ct2/show/NCT00001756

Aug 4th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04910685

Jul 28th, 2022 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...

(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT04996875

Jul 12th, 2022 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
https://clinicaltrials.gov/ct2/show/NCT03770273

Jul 7th, 2022 - Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous ...

Relevance of the Self-assessment of Skills for Self-administration of Adrenaline by Auto-injectors in Patients at Risk of Severe Anaphylactic Reaction (PacAdré)
https://clinicaltrials.gov/ct2/show/NCT05404165

Jun 3rd, 2022 - Intramuscular Adrenaline is the standard treatment for severe to moderate anaphylaxis. Self-administration of Adrenaline by the patient using an auto-injector pen in case of anaphylaxis is a major axis of management of patients with severe food al...

see more →

News  65 results

Avapritinib Approved in Europe for Advanced Systemic Mastocytosis
https://www.onclive.com/view/avapritinib-approved-in-europe-for-advanced-systemic-mastocytosis

Mar 25th, 2022 - The European Commission has expanded the current indication for avapritinib (Ayvakyt) to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast ...

2021 Approvals Expand Access to Care for Patients Across Tumor Types
https://www.onclive.com/view/2021-approvals-expand-access-to-care-for-patients-across-tumor-types

Mar 10th, 2022 - Last year marked the 50th anniversary of the National Cancer Act of 1971, a landmark legislation that committed to funding biomedical research, establishing oncology training programs, and building a nationwide network of cancer treatment centers....

EU Panel Recommends Avapritinib for Advanced Systemic Mastocytosis
https://www.onclive.com/view/eu-panel-recommends-avapritinib-for-advanced-systemic-mastocytosis

Jan 31st, 2022 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended to expand the current indication for avapritinib (Ayvakyt) to include use as a single agent in the treatment of adult patients with aggressive sy...

New Trials in Leukemia: Could Your Patient Benefit?
https://www.medscape.com/viewarticle/962196

Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
https://www.onclive.com/view/advanced-systemic-mastocytosis-expert-insight-into-epidemiology-diagnosis-and-treatment

Sep 15th, 2021 - SYSTEMIC MASTOCYTOSIS (SM) is a rare disease that often first presents on the skin. It is characterized by the overaccumulation of mast cells (MCs), which can then penetrate such internal organs as bone marrow (BM).¹ Challenges in identification a...

see more →